VectivBio Holding AG

VectivBio Holding AG is a clinical stage biopharmaceutical company specializing in the discovery, development, and commercialization of medicines for severe rare conditions. The company's primary focus is on the development of apraglutide, a long-acting synthetic peptide analog of glucagon-like peptide-2. Apraglutide is currently in Phase III clinical trials for the treatment of patients with short bowel syndrome-intestinal failure (SBS-IF) and in Phase II clinical trials for SBS-IF in patients with colon-in-continuity anatomy, as well as for patients with steroid-refractory gastrointestinal acute versus host disease (aGvHD).

Products

• Apraglutide for short bowel syndrome-intestinal failure (SBS-IF)

• Apraglutide for steroid-refractory gastrointestinal acute versus host disease (aGvHD)